Clinical data | |
---|---|
Trade names | Voydeya |
Other names | ACH-4471 |
License data | |
Routes of administration | By mouth |
Drug class | Complement factor D inhibitor |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.398.865 |
Chemical and physical data | |
Formula | C6H3BrFN7O3 |
Molar mass | 320.038 g·mol−1 |
3D model ( JSmol) | |
| |
|
Danicopan, sold under the brand name Voydeya, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria. [2] It is a complement inhibitor which reversibly binds to factor D to prevent alternative pathway-mediated hemolysis and deposition of complement C3 proteins on red blood cells. [2]
Danicopan was approved for medical use in Japan in January 2024, [3] and in the United States in March 2024. [1] [4]
Danicopan is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria. [1] [2]
In February 2024, the Committee for Medicinal Products for Human Use of the EMA adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Voydeya, intended as add-on therapy to ravulizumab or eculizumab for the treatment of residual hemolytic anemia in adults with paroxysmal nocturnal hemoglobinuria (PNH). [2] [5] The applicant for this medicinal product is Alexion Europe. [2]
Danicopan is the international nonproprietary name. [6]